The results from tri-modality system further confirm that B.breve-IL-24 could offer a novel, safe, and clinically acceptable therapeutic approach for tumor therapy in vivo, which might contribute to preoperative prediction and intraoperative monitoring of tumors. Here, IL24 is linked to neoplasm.